<?xml version="1.0" encoding="UTF-8"?>
<document
    xmlns="http://maven.apache.org/XDOC/2.0"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://maven.apache.org/XDOC/2.0
    http://maven.apache.org/xsd/xdoc-2.0.xsd">
    <properties>
        <title>Examples</title>
        <author email="michael-schnieders@uiowa.edu">Michael J. Schnieders</author>
    </properties>
    <body>
        <section name="Examples">
            <table>
                <tr>
                    <th>Module</th>
                    <th>Example</th>
                </tr>
                <tr>
                    <td>Algorithms</td>
                    <td>
                        <a href="modules/algorithms/examples.html">
                            Water Solvation Free Energy
                        </a>
                        <a href="modules/algorithms/gauche.html">
                            Organic Crystal Deposition/Sublimation Free Energy
                        </a>
                    </td>
                </tr>
                <tr>
                    <td>Potential</td>

                    <td>
                        <a href="modules/potential/examples.html">
                            Dihydrofolate reductase (DHFR) in Water
                        </a>
                    </td>
                </tr>
                <tr>
                    <td>Rotamer Optimization via Many-Body Dead-End Elimination</td>
                    <td>
                        <a href="dee.html">
                            Application to C1QTN5
                        </a>
                    </td>
                </tr>
                <tr>
                    <td>X-ray Refinement</td>
                    <td>
                        <a href="modules/xray/examples.html">
                            AMOEBA-assisted refinement at high and low resolution
                        </a>
                    </td>
                </tr>
            </table>
        </section>
        <section name="Space Group Symmetry">
            <p>
                Force Field X implements state-of-the-art features for crystals.
            </p>
            <table>
                <tr>
                    <th>Chaperonin Unit Cell</th>
                    <th>Chaperonin Asymmetric Unit</th>
                </tr>
                <tr>
                    <td bgcolor="white" align="center">
                        <img align="middle" src="images/mmcpn.P1.png" alt="P1"/>
                    </td>
                    <td bgcolor="white" align="center">
                        <img align="middle" src="images/mmcpn.C2.png" alt="C2"/>
                    </td>
                </tr>
                <tr>
                    <td>
                        <p>Force Field X can be used to simulate the unit cell of this chaperonin crystal,
                            which contains 4 copies of the asymmetric unit.
                        </p>
                        <p>Advantages include:</p>
                        <ul>
                            <li>Fluctuations of each asymmetric unit are correlated, but not strictly symmetric.</li>
                            <li>For thermodynamic averages, each sample contains 4 observations of any asymmetric unit property.</li>
                        </ul>
                    </td>
                    <td>
                        <p>Rather than apply molecular physics to the entire unit cell (P1),
                            Force Field X is also capable of using the native space group of a crystal
                            (C2 in this case).
                        </p>
                        <p>Advantages include:</p>
                        <ul>
                            <li>Crystal space group symmetry is strictly enforced.</li>
                            <li>Evaluation of the potential energy and gradients is significantly faster.</li>
                            <li>Memory requirements are significantly reduced.</li>
                        </ul>
                    </td>
                </tr>
            </table>
        </section>
        <section name="Ewald X-Ray Refinement">
            <table>
                <tbody>
                    <tr>
                        <td>
                            <font color="blue">Original (1YI4, No Electrostatics)</font>
                        </td>
                        <td>
                            <font color="blue">Ewald Refinement of the Binding Pocket</font>
                        </td>
                    </tr>
                    <tr>
                        <td bgcolor="white">
                            <p align="center">
                                <img src="images/actsite_init_small.png" alt="No Electrostatics" />
                            </p>
                        </td>
                        <td bgcolor="white">
                            <p align="left">
                                <img src="images/actsite_ffx_small.png" alt="AMOEBA PME Electrostatics" />
                            </p>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p>In collaboration with scientists at Vertex Pharmacueticals, we are using the
                polarizable AMOEBA force field evaluated using Ewald summation to re-refine
                protein-drug structures in the context of the original diffraction data (ie. using
                an X-ray likelihood target) in order to provide the most precise atomic
                resolution models possible.
            </p>
            <table>
                <thead>
                    <tr>
                        <th>Model</th>
                        <th>R/R
                            <sub>free</sub>
                        </th>
                        <th>Clash Score/%</th>
                        <th>Poor Rotamer</th>
                        <th>Rama. Favored</th>
                        <th>MolProbity Score/%</th>
                        <th>Res. (A)</th>
                        <th>Structure</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <font color="blue">Original Refinements</font>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>PIM-1 Bound to Adenosine</td>
                        <td>20.22/23.49</td>
                        <td>24.91/46
                            <sup>th</sup>
                        </td>
                        <td> 7.56%</td>
                        <td>93.92%</td>
                        <td> 2.96/33
                            <sup>rd</sup>
                        </td>
                        <td>2.4</td>
                        <td>
                            <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=1YI4">1YI4</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Staphylococcus Aureus Gyrase B with Inhibitor</td>
                        <td>23.09/32.49</td>
                        <td>33.93/20
                            <sup>th</sup>
                        </td>
                        <td> 5.45%</td>
                        <td>94.78%</td>
                        <td> 2.93/28
                            <sup>th</sup>
                        </td>
                        <td>2.3</td>
                        <td>
                            <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3G75">3G75</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Janus Kinase Bound to Inhibitor</td>
                        <td>22.07/28.60</td>
                        <td>18.87/54
                            <sup>th</sup>
                        </td>
                        <td> 5.75%</td>
                        <td>96.80%</td>
                        <td> 2.55/47
                            <sup>th</sup>
                        </td>
                        <td>2.2</td>
                        <td>
                            <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3KCK">3KCK</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Extracellular Signal-Regulated Kinase (ERK2) with Inhibitor</td>
                        <td>20.60/24.54</td>
                        <td>11.41/94
                            <sup>th</sup>
                        </td>
                        <td> 3.65%</td>
                        <td>97.26%</td>
                        <td>2.14/92
                            <sup>nd</sup>
                        </td>
                        <td>2.5</td>
                        <td>
                            <a href="http://www.rcsb.org/pdb/explore/explore.do?structureId=3I60">3I60</a>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <font color="blue">Ewald Refinements</font>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>PIM-1 Bound to Adenosine</td>
                        <td>17.76/22.37</td>
                        <td> 3.42/99
                            <sup>th</sup>
                        </td>
                        <td> 7.08%</td>
                        <td>95.85%</td>
                        <td> 2.07/91
                            <sup>st</sup>
                        </td>
                        <td>2.4</td>
                        <td>
                            <a href="structures/1YI4_Ewald.pdb">1YI4_Ewald.pdb</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Staphylococcus Aureus Gyrase B with Inhibitor</td>
                        <td>20.64/30.48</td>
                        <td> 3.74/99
                            <sup>th</sup>
                        </td>
                        <td> 5.13%</td>
                        <td>93.68%</td>
                        <td> 2.12/85
                            <sup>th</sup>
                        </td>
                        <td>2.3</td>
                        <td>
                            <a href="structures/3G75_Ewald.pdb">3G75_Ewald.pdb</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Janus Kinase Bound to Inhibitor</td>
                        <td>20.83/28.13</td>
                        <td>1.67/99
                            <sup>th</sup>
                        </td>
                        <td> 4.56%</td>
                        <td>97.17%</td>
                        <td>1.57/93
                            <sup>rd</sup>
                        </td>
                        <td>2.2</td>
                        <td>
                            <a href="structures/3KCK_Ewald.pdb">3KCK_Ewald.pdb</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Extracellular Signal-Regulated Kinase (ERK2) with Inhibitor</td>
                        <td>18.55/26.66</td>
                        <td>3.41/99
                            <sup>th</sup>
                        </td>
                        <td> 4.32%</td>
                        <td>96.96%</td>
                        <td>1.79/98
                            <sup>th</sup>
                        </td>
                        <td>2.5</td>
                        <td>
                            <a href="structures/3I60_Ewald.pdb">3I60_Ewald.pdb</a>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p>Compared to the original models, the Ewald refinements exhibit:</p>
            <ol>
                <li>Improved agreement with the data (lower R
                    <sub>free</sub> values)
                </li>
                <li>Fewer van der Waals clashes</li>
                <li>A greater percentage of favorable Ramachandran backbone conformations</li>
                <li>Overall improvement of MolProbity score</li>
                <li>Refinement of the hydrogen-bonding network within the binding pocket</li>
            </ol>
        </section>
        <section name="Homology Model Refinement">
            <p>The following structures represent a subset of the homology models available
               for genes that are implicated in hearing loss.
            </p>
            <table>
                <thead>
                    <tr>
                        <th>Model</th>
                        <th>Clash Score/Percentile</th>
                        <th>Poor Rotamer</th>
                        <th>MolProbity Score/Percentile</th>
                        <th>Structure</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>
                            <font color="blue">Original Structures</font>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>Gap Junction Beta-2 Protein</td>
                        <td>31.11/14
                            <sup>th</sup>
                        </td>
                        <td>5.13%</td>
                        <td>3.22/16
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/GJB2_2-217.pdb">GJB2</a>
                        </td>
                    </tr>
                    <tr>
                        <td>POU Domain Class 3 Transcription Factor 4</td>
                        <td>128.08/0
                            <sup>th</sup>
                        </td>
                        <td>7.52%</td>
                        <td>3.81/4
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/POU3F4_189-338.pdb">POU3F4</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Espin</td>
                        <td>67.8/1
                            <sup>st</sup>
                        </td>
                        <td>1.20%</td>
                        <td>3.08/20
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/ESPN_9-336.pdb">ESPN</a>
                        </td>
                    </tr>
                    <tr>
                        <td>
                            <font color="blue">Refined Structures</font>
                        </td>
                        <td></td>
                        <td></td>
                        <td></td>
                        <td></td>
                    </tr>
                    <tr>
                        <td>Gap Junction Beta-2 Protein</td>
                        <td> 1.12/99
                            <sup>th</sup>
                        </td>
                        <td>0.51%</td>
                        <td>1.39/97
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/GJB2_2-217_refined.pdb">CDH23_refined</a>
                        </td>
                    </tr>
                    <tr>
                        <td>POU Domain Class 3 Transcription Factor 4</td>
                        <td>1.23/99
                            <sup>th</sup>
                        </td>
                        <td>0.00%</td>
                        <td>1.28/99
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/POU3F4_189-338_refined.pdb">POU3F4</a>
                        </td>
                    </tr>
                    <tr>
                        <td>Espin</td>
                        <td>1.66/99
                            <sup>th</sup>
                        </td>
                        <td>0.40%</td>
                        <td>1.55/94
                            <sup>th</sup>
                        </td>
                        <td>
                            <a href="structures/ESPN_9-336_refined.pdb">ESPN_refined</a>
                        </td>
                    </tr>
                </tbody>
            </table>
            <p>The homology models after the refinement procedure display:</p>
            <ol>
                <li>Significantly fewer steric clashes</li>
                <li>A higher degree of favorable side chain conformations</li>
                <li>Substantial improvement in the Molprobity score</li>
            </ol>
        </section>
    </body>
</document>
